Navigation Links
Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Date:7/31/2008

(in thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30,

Pro Forma Pro Forma

2008 2007 2008 2007

(in thousands, except per share data)

Numerator:

Pro forma net income allocable to

common stockholders $5,571 $3,767 $10,578 $5,092

Denominator:

Weighted average shares of common

stock outstanding 16,380 230 16,283 214

Weighted average unvested shares of

common stock subject to repurchase (43) (52) (48) (48)

Adjustments to reflect the weighted

average effect of the assumed

conversion of convertible preferred

stock - 11,032 - 11,032

Pro forma weighted average shares of

common stock outstanding - basic 16,337 11,210 16,235 11,198

Dilutive effect of common equivalent

shares 1,175 1,548 1,272 1,547

Pro forma weighted average shares of

common stock outstanding - diluted 17,512 12,758 17,507 12,745

Pro forma net income per share:

Basic $0.34 $0.34 $0.65 $0.45

Diluted $0.32 $0.30 $0.60 $0.40

(1) As a result of the conversion of the Company's preferred stock into 11,032 shares of common stock upon completion of the Company's initial public offering in November 2007, there is a lack of comparability in the basic and diluted net income per share amounts for the periods presented above.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genoptix Reports Strong Financial Results for First Quarter 2008
2. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
3. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
4. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
5. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
6. Genoptix Announces Pricing of Secondary Public Offering
7. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
8. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
9. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
10. Genoptix, Inc. Announces Pricing for Initial Public Offering
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Regularly checking the pulse ... researchers report. "Screening pulse is the method of ... age 65 who have never had a stroke. Our ... and easy way to identify people who might need ... study author Dr. Bernd Kallmunzer, of Erlangen University in ...
(Date:7/23/2014)... National Institute of Biomedical Imaging and Bioengineering will host ... July 30, 2014 on the NIH campus. There will ... a wide breadth of NIBIB-funded research. , ... Engineering Microbial Rhodopsins as Optical Voltage Sensor, Quyen ... Probes for Nerve Imaging during Surgery, ...
(Date:7/23/2014)... Los Angeles, CA (PRWEB) July 23, 2014 ... physician practices delivering Enhanced External Counterpulsation (EECP), ... patient who receives EECP therapy at the health center. ... and ischemic heart disease. Since receiving ongoing EECP therapy ... , When Sara Soulati, CEO of Global Cardio ...
(Date:7/23/2014)... RIVERSIDE, Calif. Fragile X syndrome ( FXS ) ... behaviors, and other behaviors on the autistic spectrum, as ... inherited cause of mental impairment and the most common ... University of California, Riverside have published a study ... behaviors in FXS. Appearing online today (July 23) in ...
(Date:7/23/2014)... PA (PRWEB) July 23, 2014 Four ... have been lauded in the latest ranking of the ... Report . Released online today and slated for ... Guide recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint ... medical centers across multiple clinical specialties. , ...
Breaking Medicine News(10 mins):Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3
... Va., April 16 Since the inaugural National ... than one million advance directive forms have been ... Organization,s Caring Connections program. Today, the 2nd Annual ... age or current health are reminded of the ...
... #H1/F38 - Varian Medical Systems, Inc. (NYSE: VAR ... digital X-ray image detectors will exhibit its line of PaxScan ... the China International Medical Equipment Fair (CMEF) meeting in Shenzhen, ... showcase its full range of X-ray tubes for fluoroscopy, angiography, ...
... For His Discoveries About Attention And Memory, ... 16 NeuroFocus, the world leader in ... application of brainwave-based measurements for market research ... named a Partner in the company,s Consulting ...
... BLOOMINGTON, Minn., April 16 Pearson VUE, the ... it has signed an exclusive agreement with the ... be the exclusive test delivery provider of the ... CCMA examinations are delivered throughout the secure Pearson ...
... Chance to Look Like a Star with Milk on ... Only at bodybymilk.comWASHINGTON , April 16 Warding ... superheroes like Wolverine need a little help. (Photo: ... to rebuild his body far faster than any ordinary ...
... the disease, not the symptoms)HUDSON, Fla., April 16 Workforce Prescriptions ("WRX") announced on ... their unique labor waste derived from 7 sources: , , ... Agency utilization , Other "Premium Pay" ... avoidable days , Process labor waste , ...
Cached Medicine News:Health News:2nd Annual National Healthcare Decisions Day Builds on Growing Awareness of Advance Care Planning 2Health News:Varian Medical Systems to Exhibit the Latest X-Ray Image Detectors, and X-Ray Tubes at the CMEF Show in Shenzhen, China 2Health News:NeuroFocus Appoints Dr. Michael Smith as Partner in Consulting Practice 2Health News:California Certifying Board for Medical Assistants Signs Exclusive Contract with Pearson VUE 2Health News:X-Men's Wolverine Depends on Milk as His X-factor 2Health News:WRX Launches Hospital Labor Waste Calculator 2Health News:WRX Launches Hospital Labor Waste Calculator 3
(Date:7/23/2014)... 23, 2014 Research and Markets ... Gloves (Exam and Surgical) Markets Worldwide 2014" report ... The purpose of this report is ... Medical (Exam and Surgical) Gloves. The report discusses key ... products. Topics covered include product definitions, strategies, ...
(Date:7/23/2014)... , July 23, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... new drug application ("IND") with respect to its ... announced today that it has received an additional ... ("NIDA"), part of the National Institutes of Health ...
(Date:7/23/2014)... , July 23, 2014 This September leading ... Las Vegas for DOCtalk ... educator, author, forward thinker and private practitioner Dr. ... together to candidly discuss clinical and practice management efficiency ... is a unique opportunity to welcome fresh thinking and ...
Breaking Medicine Technology:Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 32014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3
... Therapeutics,today announced the presentation of data on the ... American Transplant,meeting to be held in San Francisco, ... with scientists at the University of,Western Ontario., "These ... extend graft,survival in transplantation, and that it can ...
... at Least 75 Percent Improvement in Psoriasis,Signs and ... Dosing Groups, More,Than Half Achieved 90 Percent Improvement, ... New,Phase II study results show Abbott's investigational treatment,ABT-874, ... treated. At 12 weeks, nine out of 10 ...
Cached Medicine Technology:Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 3Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: